Corrigendum: Optimized riboswitch-regulated AAV vector for VEGF-B gene therapy

Front Med (Lausanne). 2023 Mar 3:10:1143748. doi: 10.3389/fmed.2023.1143748. eCollection 2023.

Authors

Reetta A E Eriksson^{1

2}, Tiina Nieminen¹, Lionel Galibert¹, Sanna K Peltola¹, Petra Tikkanen¹, Piia Käyhty^{1

2}, Hanna M Leinonen¹, Igor Oruetxebarria¹, Saana Lepola¹, Anniina J Valkama¹, Eevi M Lipponen¹, Hanna P Lesch¹, Seppo Ylä-Herttuala^{2

3}, Kari J Airenne¹

Affiliations

¹ Kuopio Center for Gene and Cell Therapy, Kuopio, Finland.
² A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
³ Gene Therapy Unit and Research Center, Kuopio University Hospital, Kuopio, Finland.

Abstract

[This corrects the article DOI: 10.3389/fmed.2022.1052318.].

Keywords: AAV (adeno-associated virus); ON-switch; VEGF-B; gene therapy; riboswitch; tetracycline; transgene expression regulation.

Copyright © 2023 Eriksson, Nieminen, Galibert, Peltola, Tikkanen, Käyhty, Leinonen, Oruetxebarria, Lepola, Valkama, Lipponen, Lesch, Ylä-Herttuala and Airenne.

Publication types

Published Erratum